Core Scientific, Inc.
CORZQ
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.04% | -9.63% | -34.21% | -42.24% | -53.79% |
| Total Other Revenue | 4.72% | 25.07% | 30.24% | 21.90% | -1.88% |
| Total Revenue | 1.65% | 15.77% | 8.25% | -1.30% | -21.54% |
| Cost of Revenue | -0.41% | -11.39% | -25.33% | -34.53% | -40.03% |
| Gross Profit | 7.97% | 343.01% | 3,223.26% | 667.78% | 1,369.75% |
| SG&A Expenses | 31.43% | 5.77% | -22.58% | -54.16% | -54.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -14.04% | 1,902.60% | 332.99% | -95.48% | -97.63% |
| Total Operating Expenses | 6.95% | -6.54% | -23.54% | -48.16% | -53.99% |
| Operating Income | -237.27% | 136.24% | 141.06% | 115.85% | 102.55% |
| Income Before Tax | -434.63% | -145.54% | 6.70% | 98.01% | 88.64% |
| Income Tax Expenses | 25.77% | 103.88% | 107.54% | 101.32% | 104.00% |
| Earnings from Continuing Operations | -433.50% | -156.39% | 5.49% | 97.89% | 88.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -433.50% | -156.39% | 5.49% | 97.89% | 88.52% |
| EBIT | -237.27% | 136.24% | 141.06% | 115.85% | 102.55% |
| EBITDA | -8.14% | 192.92% | 474.61% | 187.89% | 152.78% |
| EPS Basic | -737.95% | -340.37% | -81.68% | 105.68% | 89.82% |
| Normalized Basic EPS | -3,265.67% | -2,205.32% | -761.05% | 117.15% | 86.88% |
| EPS Diluted | -750.55% | -351.32% | -87.71% | 102.68% | 89.73% |
| Normalized Diluted EPS | -3,307.96% | -2,237.59% | -777.36% | 110.97% | 86.88% |
| Average Basic Shares Outstanding | -33.62% | -29.50% | -22.23% | -6.04% | 8.89% |
| Average Diluted Shares Outstanding | -30.23% | -26.15% | -18.82% | -2.52% | 8.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
